Recipharm AB is collaborating with Vectura Group plc to provide access to its license for the regulatory dossier of Asmasal for Chinese market approval. The regulatory submission will be led by Vectura’s new strategic joint venture, Tianjin Kinnovata Pharmaceutical Co. Ltd.   Asmasal Clickhaler is a dry powder inhaler with the active ingredient salbutamol, which is used in conditions where there is narrowing of the airways, such as asthma or COPD.  Vectura’s Clickhaler device allows the active t...